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Abstract 
Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV) co-infections are common all over the world. 
Infection with HIV increases rates of HBV chronicity, prolong the time the HBV stays in circulation and increase 
liver-related morbidity. Factors such as intravenous drug use, multiple blood transfusions, presence of tattoos, 
unsafe sexual practices and being health workers have been implicated as drivers of infection & transmission of 
HBV & HIV. This study aimed to determine the prevalence and genotypes of HBV associated risk factors among 
HIV infected patients in a descriptive cross-sectional study. Malindi was chosen as a suitable study site because 
of the high numbers of residents involved in sex tourism as well as intravenous drug use. A structured questionnaire 
was used to capture social demographic data such as age, gender, employment status, occupation, the level of 
education and marital status, clinical history information such as duration since diagnosis with HIV, ART drug 
history, duration taking ARVs and baseline CD4 count and risk factors associated with HBV infections such as 
intravenous drug use, history of blood transfusion, tattooing/scarification, and the sexual history from 446 
consenting randomly selected HIV infected participants. Five millilitres of whole blood was obtained from each 
participant, 50µl of which was used for CD4 cell counts using a flow cytometer. HBsAg serology was done using 
Diaspot® rapid diagnostic test and confirmed by Hepanostika® HBsAg Ultra ELISA kit (BioMérieux SA) and 
HBV DNA was extracted from all HBsAg positive samples. Nested polymerise chain (PCR) reaction and 
sequencing of the Pre S1 region was done. Sample sequences were compared with published HBV genotypes 
sequences from GenBank and Phylogenetic trees were constructed using the NJ Plot software using a PHB file 
created through DNA Database of Japan (DDBJ) to determine the HBV genotypes. Out of the 446 HIV positive 
participants, 126 (28.3%) were males and 320 (71.7%) females. Only 19/446 (4.26%) participants were positive 
for HBV based on rapid strip test while 22/446 (4.93%) participants had HBV based on ELISA. Twelve of the 22 
ELISA positive samples were successfully amplified by PCR. Out of the 12 PCR positive samples 10 were 
successfully sequenced. Phylogenetic analysis revealed that 9/10 (90%) samples belonged to genotype A while 
1/10 (10%) belonged to genotype E. Males (p=0.028) and intravenous drug use (p= 0.08) were significantly 
associated HBV infections. The high prevalence (4.9%) of HBV among HIV patients attending Malindi Sub-
county hospital is most likely highly driven by intravenous drug use and multiple sexual partners among the male 
gender and is predominantly genotypes A and E which is similar to the general population. 
Keywords: Hepatitis B virus, HIV, Co-infection, HBsAg, genotypes, intravenous drug use 
 
Introduction 
Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) are major public health problems and are 
among the 10 highest causes of infectious deaths in the world (Alter, 2006). The two viruses share similar routes 
of transmission (Alter, 2006, Otedo, 2004) with HBV having a hundred fold efficiency in transmission compared 
to HIV (Otedo, 2004). Individuals with HIV-HBV co-infection have higher HBV DNA levels (Dore et al., 2010) 
which is associated with the immune deficiency due to HIV which in turn translates to increased HBV disease 
progression (Diwe et al., 2013). On top of this, increased mortalities and morbidity in HIV patients as a result of 
liver disease are partly due to co-infection with HBV and HCV since these viruses increase intra-hepatic apoptosis 
which is a consequence of liver fibrosis (Diwe et al., 2013).   
In the world, it’s approximated that 33 million people are infected with HIV and among these about 3 million 
(10%) are co-infected with HBV (Kourtis et al., 2012). In Kenya the prevalence of HBV-HIV co-infection has 
been reported to be as high as 6% and significantly higher in males 19.2% compared to 14.2% in females in a 
study done among several Nairobi based health centres. (Muriuki et al., 2013). 
HBV has a wide genetic variability which has resulted into the emergence of 10 genotypes with several sub-
genotypes which are labelled alphabetically from A-J (Tangkijvanich et al., 2013). There is remarkable evidence 
suggesting that HBV genetic variability is an important factor in determining disease progression and also response 
to antiviral treatment (Poukarim et al., 2011).  In East Africa where Kenya resides, genotype A is the most 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.7, No.22, 2017 
 
63 
prevalent (88%) followed by genotype E (8%) and then Genotype D (4%) (Mwangi et al., 2008). Webale et.al 
(2015) reported 100% genotype A1 among HIV-1 infected and non-infected injecting and non-injecting drug users 
in coastal Kenya. Genotype A1 had also been reported exclusively among HIV infected IDUs from Mombasa, a 
region along the Kenyan coast. (Kibaya et al., 2015) 
HBV is more prevalent among HIV–infected individuals than in the general population which can be 
attributed to the shared risk factors for transmission and acquisition of these two life threatening viruses (Chen et 
al., 2013). Some of these risk factors associated with the transmission of HIV and HBV include: involvement in 
intravenous drug use, scarification/tattooing, having several heterosexual partners/involvement in commercial sex, 
male having sex with men and occupational hazards for health workers (Alter, 2006, Chen et al., 2013, Ranjbar et 
al., 2013).  
The primary aim of this study was to determine the prevalence of HBV and circulating genotypes among HIV 
positive participants attending the comprehensive care clinic at Malindi Sub-county hospital.  The diversity of 
countries of origin of the tourists to this area and their interaction with the local people would arouse the 
epidemiological curiosity about the introduction of new strains, their genetic diversity and the implications on the 
clinical presentation of disease in cases where patients are co-infected. Characterization of HBV among the HIV 
patients will help in understanding the distribution of specific genotypes in the study setting. The genetic pattern 
of the virus will in turn help policy makers and clinicians in making sound decisions during prescription of drugs 
to these patients since different HBV genotypes have different responses to the antiretroviral drugs. 
 
Methods 
Study site and patients recruitment  
This was a descriptive hospital based cross sectional study carried out between May 2015 and April 2017 at the 
Comprehensive Care Centre (CCC) at the Malindi sub-county hospital. Malindi was selected as a suitable study 
site because it is located along the coastal strip of Kenya, a region that is popular with tourists both local and 
foreign. Foreign tourist in Malindi come from all over the world with the Italians, Germans and those from the 
United Kingdom topping the list. This region is on record for having a fairly large population of persons who 
engage in sex tourism as well as recreational intravenous substance abuse and in some cases they may share needles 
to inject themselves with the narcotics and/or engage in unprotected sexual contact. Simple random sampling was 
used to recruit patients aged 18 years (due to ethical issues) and only those from the CCC. Any vulnerable persons 
such prisoners and the mentally challenged were not recruited for the study. Participation was upon providing a 
written informed consent. Those who were randomly selected and did not consent were not recruited and hence 
replaced. 
 
Data on socio-demographic, clinical and associated risk factors 
A study questionnaire was designed to obtain information from patients and also from the patient’s hospital records. 
The information captured in the questionnaire included: social demographic characteristics including Age, gender, 
employment status, the level of education and marital status, Clinical history of patients including Duration since 
diagnosis with HIV, ART drug history, duration taking ARVs and baseline CD4 count. The questionnaire also 
sought to obtain information on risk factors associated with transmission of HIV and HBV including Intravenous 
drug use, history of blood transfusion, tattooing/scarification, and the sexual history. The questionnaire was 
administered in a confidential counselling room by a professional counsellor who was recruited for this study. 
 
Sample collection, processing, shipping and storage  
Five millilitres of blood was collected aseptically into EDTA vacutainer bottles (BD New Jersey, USA) using 
venepuncture. Fifty microliters (50µl) of the sample were analysed for CD4 counts within 24 hours of collection 
through flow cytometry using the BD Facs Caliber machine. The samples were then separated using centrifugation 
at 3000 RPM for 10 minutes and the plasma stored at -20 C. The samples were then packaged⁰  using the basic 
triple packaging system according to the International Air Transport Association (IATA) regulations. This 
included primary receptacles (screw capped containers ) which were leak proof covered with a layer of absorbent 
material, a secondary receptacle (zip lock bags) which was also leak proof enclosing the primary receptacle and 
finally a leak-proof  outer packaging i.e. cool box  labelled with an easily noticeable biohazard symbol. The 
samples were then transported to KEMRI under a cold chain through a paid for courier services. After un-
packaging they were stored at -80 C until serological and molecular tests were done.⁰  
 
HBV serology.  
The samples were screened for HBsAg using the DiaSpot® HBsAg test kit which is a rapid one step test for the 
qualitative detection of HBsAg and Hepanostika® HBsAg Ultra ELISA kit (BioMérieux SA) which is based on a 
“sandwich” principle. The tests were done according to the manufacturer’s instructions. 
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DNA extraction and PCR amplification of HBV PRE S1 region 
DNA from the 22 samples that tested positive for HBsAg was extracted from 50µl of plasma using Qiagen® DNA 
extraction kit (Qiagen) using the manufactures instructions. Extracted DNA was used as template in a PCR to 
amplify the Pre S1 (681bp) region by nested PCR using a set of primers (table1). To describe this briefly, the 
master mix for the first amplification included 2.5µl of 10x PCR buffer, 2.0µl of 10mM dNTPs, 0.3µl of first set 
of primer S1F and S1R (Table 1), 1µl Taq polymerase and 5µl of extracted DNA. 
Table 1: Primers used for HBV PCR amplification and sequencing 
Primers Nucleotide position Sequences Expected fragment 
size region (bp) 
PS1 forward 55-72 TCCTGCTGGTGGCTCCAG 940 
PS1 Reverse 995-974 CGTTGACATACTTTCCAATCAA 
PS2 Forward 155-173 ACCCTGYRCCGAACATGGA 680 
PS2 Reverse 835-814 CAACTCCCAATTACATARCCCA 
The PCR conditions started at 94⁰C for 7 minutes, followed by 38 cycles of 94⁰C for 40 seconds, 60⁰ C for 
1 minute and 72⁰ C for 2 minutes and final extension for 72⁰ C for 15 minutes. The second master mix will include 
5µl of 10x PCR buffer, 1.5µl magnesium chloride, and 4.0µl of dNTPs, 0.25µl of second set of primer S2F and 
S2R (table 1) and 2µl Taq polymerase. Visualization of amplified DNA was done on 1.2% agarose gel in 1x TAE 
buffer stained with ethidium bromide.  
 
Sequencing and viral genotyping 
Purified PCR products were directly sequenced using BigDye terminator v3.0 in a Sequencing Ready Reaction 
Kit (Macrogen Inc, Korea) using the 2nd PCR primers S2F and S2R (table 1). The sequencing reactions were 
performed using ABI3730 automated sequencer (Applied Bio systems). The resulting forward and reverse 
sequences from each sample were assembled using the GENETYX® Ver.9 software. The sequences were aligned 
with references sequences from gene bank and trimmed with MEGA 7.0.25 software. Phylogenetic relationship 
were inferred by creating a PHB file through the DNA Data bank of Japan (DDBJ) and opening the file through 
NJ plot software. 
 
Ethical consideration 
The study was ethically approved by the KEMRI scientific steering committee (SSC) and the Ethical review 
committee (ERC) (SSC Protocol number 2913) before implementation. The study was also approved by the Kilifi 
County Research committee (Ref:DOH/KLF/RESCH/VOL.I/21) and the management of Malindi Sub-county 
Hospital. 
 
Data analysis 
Social demographic, clinical and risk factors data was entered and cleaned using Ms Excel and transferred to 
Statistical package for social sciences (SPSS) version 21. SPSS was used to analyse the frequencies, means and 
percentages for the social demographic data, clinical data and the risk factors against the HBV sero-positivity 
through cross-tabulation. Independent t test was used for comparison of means for the CD4 counts between the 
HIV mono-infected and HIV-HBV mono-infected. STATA was used to perform bivariate and multivariate 
analysis to determine factors associated with HBV infections using Poisson regression with significance set at P ≤ 
0.05 and odds ratio with corresponding 95% confidence interval. 
 
Results 
Baseline characteristics of study participants 
A total of 446 HIV positive participants including 126 (28.3%) males and 321(71.8%) females were enrolled for 
the study. Their ages ranged from 18-76 years with a mean age of 42.98 +/-10.750 years. The mean age of males 
was 44.93 years (SD ±10.16) while that of females was 42.22 years (SD ±10.88). Other baseline characteristics of 
the study participants have been summarised in table 2 
At the time of sample collection 69 (15.5%) individuals had not started ARVS. Those who were taking AZT, 
3TC, NVP regimen were the majority (33.4%) while 26.9% were on 3TC, TDF, EFV. The rest (24.2%) were on 
TDF, 3TC, NVP 
  
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.7, No.22, 2017 
 
65 
Table 2- Baseline characteristics among HIV positive patients attending Malindi sub-county Hospital 
Variable Sample size (N = 446) 
  No % 
Age (Years)     
Mean (± SD) 42.98  (± 10.75)  
Median (IQR) 43  (34.75 - 50) 
Range 58 (18 - 76) 
≤30 62 13.9 
31-40 125 28.1 
41-50 158 35.4 
≥50 101 22.6 
Gender   
Males 126 28.3 
Females 320 71.7 
Level of Education     
Primary 240 53.8 
Secondary  77 17.3 
Tertiary 21 4.7 
none 108 24.2 
Employment status     
employed/self employed 246 55.2 
unemployed 200 44.8 
Marital status     
Single 48 11 
Married 236 53 
widow/divorced 162 36 
ARV drug currently on use     
3TC, TDF, EFV 120.0 26.9 
AZT, 3TC, NVP 149 33.4 
TDF,3TC, NVP 108 24.2 
Not started 69 15.5 
CD4 count     
Mean (± SD) 417.49. (±239.643) 
  Median (IQR) 403.5     (247.5-562) 
              Range 1331        0-1331 
CD4 less 500 292 65.5 
CD4 ≥500 154 34.5 
Duration Since HIV diagnosis   
0-5 yrs 227 50.9 
6-10 yrs 204 45.7 
˃10yrs 13 3.4 
Duration since ART initiation   
0-5 yrs 264 59.2 
6-10 yrs 175 39.2 
˃10yrs 7 1.6 
Intravenous Drug Use     
Yes 13 2.7 
no 433 97.3 
History of blood transfusion 
Yes 
  
36 
  
8.1 
No 410 91.9 
Scarification/Tatooing     
Yes  9 2 
No 437 98 
Involvement in CSW   
Yes 23 5.2 
No 423 94.8 
Sexuality     
Heterosexual 441 98.9 
Homosexual/Bisexual 5 1.1 
Number of partners in the past 6 months   
None 86 19.3 
One 329 73.8 
2 to 3 24 5.4 
≥4 7 1.6 
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Laboratory results 
A total of 19 (4.26%) participants were HBsAg positive based on rapid strip test while 22 (4.94%) participants 
were positive for HBsAg based on ELISA. All the 19 samples that were positive via the rapid test were confirmed 
positive via ELISA. Males had the highest prevalence of the HIV-HBV co-infection 11 out of 126 (8.7%) 
compared to 11 out of 320 females (3.4%). HBV DNA was successfully amplified in 12 out of 22 (54.5%) samples 
positive for HBsAg ELISA. 10 out of the 12 HBV-DNA positive samples were successfully sequenced. This has 
been summarised in table 3 
Table 3: A summary of the laboratory tests done and their results 
 HBsAg serology 
(n=446) 
HBV DNA PCR 
positive (n=22) 
HBV Sequencing 
(n=12) 
Rapid ELISA 
Positive 19 (4.26%) 22 (4.94%) 12 (54.5%) 10 (83.3%) 
Negative 427 (95.74%) 424 (95.06%) 10 (45.5%) 2 (16.7%) 
The mean CD4 count for the study population was 417.5 (SD = ±240.3 cell/µl). Although not statistically 
significant (p = 0.429) those who were HIV-HBV co-infected had a lower CD4 count (378 cell/µl) compared to 
those who were HIV mono-infected (419.5 cell/µl).. 
 
Phylogenetic analysis and genotypes 
Phylogenetic analysis revealed that 9/10 (90%) belonged to genotype A which were all categorised into sub-
genotype A1 while 1/10 (10%) belonged to genotype E. A phylogenetic tree was constructed by NJ plot software 
using a phb file generated from DNA Data Bank of Japan (DDBJ) as shown in fig 1. 
 
Fig 1: Phylogenetic analysis based on the Pre-S region from 10 HBV strains from HBV-HIV co-infected patients 
attending the Malindi Sub-County Hospital and selected reference sequences representing some of the known 
HBV genotypes/Sub-genotypes from the Genebank. The 10 HBV characterised in this study are indicated in bold 
and 9/10 fall under genotype A1 while 1/10 fall under Genotype E. The references are labelled with their accession 
numbers, country of origin and the genotype they belong to. The tree is rooted from the Woolley Monkey virus 
genome sequence. 
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Factors associated with HBV infections 
Univariate analysis showed that gender (p = 0.029) and Intravenous drug use (p = 0.008) were significantly 
associated with HBV infection whereas all other factors were not statistically significant. In Multivariate analysis 
gender (p = 0.013) and Intravenous drug use (p = 0.05) were also statistically significant (Table 4) 
Table 4: Univariate and Multivariate analysis of factors associated with HBV infection among HIV patients 
attending CCC at Malindi Sub-County Hospital. (N=446) 
Variable Sample size (N = 446)  Bivariate   Multivariate 
 No. HBV No. 
(n=22) 
HBV
%  
P - value OR (95% CI) P - value OR (95% CI) 
Gender        
Male 126 11 8.7 0.029 2.2(1.1-5.9) 0.013 3.2(1.3-8.1) 
Female 320 11 3.4 Referent Referent Referent Referent 
Age (Years)        
≤30 62 2 3.2 0.34 0.5(0.1-2.2) 0.542 0.6(0.1-3.0) 
31-40 125 4 3.2 0.218 0.5(0.1-1.5) 0.384 0.6(0.2-2.0) 
41-50 158 9 5.7 0.697 0.8(0.3-2.2) 0.961 1.0(0.4-2.7) 
˃50 101 7 6.9 Referent Referent Referent Referent 
Employment status        
employed/self employed 246 14 5.7 0.426 1.4(0.6-3.4) 0.378 1.5(0.6-3.8) 
unemployed 200 8 4 Referent Referent Referent Referent 
Level of Education        
Primary 240 14 5.6 0.92 1.1(0.4-2.7) 0.606 0.8(0.3-2.2) 
Secondary  77 1 1.3 0.178 0.2(0-1.9) 0.056 0.1(0-1) 
Tertiary 21 1 4.8 0.887 0.9(0.1-7.1) 0.511 0.5(0.1-4.3) 
Non formal 108 6 5.6 Referent Referent Referent Referent 
Marital status        
Single 48 1 2.1 0.352 0.4(0.0-3.0) 0.532 0.5(0.1-4.2) 
Married 236 12 5.1 0.841 0.9(0.4-2.1) 0.514 0.7(0.3-1.8) 
Widow/Widower/Divorced 162 9 5.6 Referent Referent Referent Referent 
ARV drug currently on use        
3TC, TDF, EFV 120.0 8 6.7 0.15 4.6(0.6-36.8) 0.995 0 
AZT, 3TC, NVP 149 10 6.7 0.144 4.6(0.6-36.2) 0.995 0 
TDF,3TC, NVP 108 3 2.8 0.573 1.9(0.2-18.4) 0.995 0 
Not started 69 1 1.4 Referent Referent Referent Referent 
CD4 count        
Less than 500 292 16 5.5 0.476 1.4(0.6-3.6) 0.433 1.5(0.6-3.9) 
Greater than 500 154 6 3.9 Referent Referent Referent Referent 
Duration since HIV diagnosis        
0-5yrs 227 9 4 0.995 0 1 0 
6-10yrs 204 13 6.4 0.965 0 1 0 
˃10yrs 15 0 0 Referent Referent Referent Referent 
Duration since ARV initiation        
0-5yrs 264 11 4.2 0.996 0 0.999 0 
6-10yrs 175 11 6.3 0.996 0 0.999 0 
˃10yrs 7 0 0 Referent Referent Referent Referent 
Intraveneous drug use        
Yes 13 3 23.1 0.008 5.3(1.6-17.8) 0.05 4.1(1.0-16.6 
no 433 19 4.4 Referent Referent Referent Referent 
History of blood transfusion        
Yes 36 0 0 1 0 0.995 0 
No 410 22 5.4 Referent Referent Referent Referent 
Scarification/Tatooing        
Yes  9 0 0 0.999 0 0.997 0 
No 437 22 5 Referent Referent Referent Referent 
CSW        
Yes 23 1 4.3 0.897 0.9(0.1-6.5) 0.813 0.8(0.1-6.0) 
No 423 21 5 Referent Referent Referent Referent 
Sexuality        
Homosexual 1 0 0 1 0 0.999 0 
Bisexual 4 0 0 1 0 0.998 0 
Heterosexual 441 22 5 Referent Referent Referent Referent 
No. of patners in past six months        
One 329 14 4.3 0.161 0.5(0.2-1.3) 0.398 0.7(0.2-1.7) 
2 to 3 24 1 4.2 0.531 0.5(0.1-4.2) 0.846 0.8(0.1-8.8) 
≥4 7 0 0 0.994 0 0.998 0 
None 86 7 8.1 Referent Referent Referent Referent 
 
Discussion 
Several studies have been carried out in Sub-Saharan Africa including Kenya to access the burden of hepatitis B 
virus among HIV infected individuals. However majority of this studies focus on populations that form risk sub-
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populations for HIV and HBV transmission or newly diagnosed HIV patients. The present study focused 
prevalence, risk factors and genotypes of HBV in a generalized HIV infected patients population receiving medical 
care in one of government hospital set up in Kilifi County.  
Generally, the prevalence of HBV is higher among HIV–infected individuals than in the general population 
which can be attributed to the shared risk factors for transmission and acquisition of these two life threatening 
viruses (Chun et al., 2012). The present study reported a HBV prevalence of 4.9% (22/446) among HIV positive 
participants based on laboratory analysis of HBsAg through ELISA. The rates of HIV-HBV co-infections have 
previously been reported to be as high as 10–20% in countries where HBV infection is either endemic or 
intermediate to high HBV cases (Muriuki et al., 2013). In Kenya, a study by Muriuki et al., 2013 on the prevalence 
of HBV and HIV co-infection showed a prevalence of 6% with co-infection rates significantly higher among males 
(19.2%) compared to females (14.3%). This result was also in agreement with other studies carried out in Kenya 
including; 5.7% (Wambani et al., 2015), 4.26 % (Kerubo et al., 2015) and 3.6 % as reported by Webale et al., 
(2015) among HIV positive non-IDUs in Mombasa, Coastal Kenya. The results were also similar to those reported 
in other parts of the world including 5.2 % in Morocco (Rebbani et al., 2013) and 3.8 % in Brazil (Brandaoa et al., 
2015). In South Africa between 5% and 17% of HIV-infected patients in the country were found to be co-infected 
with Hepatitis B virus ( Chun et al., 2012).  
The results of this study were found to be lower than those of other studies carried out in other studies 
including jaundiced patients in Kenya which reported 53 % (Otedo, 2004) and 50.6 % (Ochwoto et al., 2016), 
25.5 % among HIV patients in Morocco (Magoro et al., 2016), 19.2 % among HAART naïve patients in China 
(Chen et al., 2013), 12 % among HIV patients in Columbia (Bautista et al., 2014), 10.5 % among HIV patients in 
Lesotho (Mugomeri et al., 2015), 9.6 % among HIV IDUs in Mombasa, Kenya (Webale et al., 2015). The higher 
HBV prevalence rates in this studies compare to the current study could have been as a result of using sub-
populations that have evident signs associated with HBV such as the jaundiced patients who were attending clinics 
due to liver related complication, being selected from HBV high risk sub-populations such as the intravenous drug 
users or newly diagnosed patients who had not started ART.  
On the other hand, the results reported in this study were contrarily higher compared to reports from Nigeria 
as reported by Dore et al., (2010) and  Diwe et al., (2013) indicating HBV/HIV prevalence rates of 2.4% and 2.2% 
respectively, 2.2 % in Malawi (Varo et al., 2016) and 2.5 % in Brazil (Freitas et al., 2014). The higher prevalence 
rate in the present study could be as a result the samples being collected from a HBV prevalence intermediate (2-
7%) area as classified by WHO (Zenebe et al., 2014). As reported by Mukami et al., (2013) other factors that 
might have resulted in disparities in the prevalence rates between this studies result and those conducted in other 
places could include but not limited to sample size used, specificity and sensitivity of kits used and diversity of 
behavioural characteristics of each population. 
Phylogenetic analysis of the HBV genotypes in the current study revealed the presence of genotype A (90%) 
and E (10%) as would be expected of the Kenyan population. This observation is in agreement with other studies 
done in Kenya that reported a prevalence of 88% (Mwangi et al., 2008), 90.3 % (Ochwoto et al., 2016), 100 % 
(Webale et al.,2015) of genotype A1. Mwangi et al., (2008) had also reported genotype E although at a much lower 
prevalence than genotype A. All the genotype A sequences belonged to the HBV genotype A1 sub-genotypes. 
Five of the genotype A and the genotype E sequences clustered with sequences from countries in sub Saharan 
Africa including Tanzania, central Africa republic, South Africa Ivory coast and Guinea. This could be attributed 
to trade relationships between these African countries. The rest four sub-genotype A1 samples clustered with 
samples from Somalia and the Asian clade (Phillipines and Japan). This could be as a result of immigrants from 
Somalia who access the Kenyan coast and tourists from the Asian countries. 
The current study looked for association between the social demographic, clinical history and risk/behavioral 
factors with HBV among HIV positive participants. Male gender was found to be significantly associated with 
HBV infection among the HIV positive participants. This finding agrees to other studies carried out in Lesotho, 
Brazil and Nigeria (Mugomeri et al., 2015, Freitas et al., 2014, Balogun et al., 2012). Contrary to the findings of 
this study, Kerubo et al., (2014) in a study involving participants from two informal settlements in Nairobi, Kenya 
did not find any association between HIV/HBV co-infection with gender. The fact that male gender is associated 
with HBV in the current study can be attributed to risky behaviours related to HBV transmission such as multiple 
sexual partners without use of protective measures and involvement in intravenous drug use more than their female 
counterparts. 
Involvement in intravenous drug use was also found to be significantly associated with HBV infection OR, 
5.3 (95% CI 1.6-17.8) among HIV participants of this study. Zenebe et al., (2014) reported that individuals who 
used injectable drugs were 5 times more likely to have HBV infections which is in tandem with the current study. 
This is a clear evidence of the efficiency of intravenous drug use in transmission of blood borne viral infections. 
Other studies have documented that factors such as increasing age (Freitas et al., 2014), blood transfusion (Zenebe 
et al., 2014, Alhuraiji et al., 2014) tattooing/scarification (Zenebe et al., 2014)  homosexuality (Freitas et al., 2014, 
Brandaoa et al., 2015) to be associated with HBV infections among HIV positive patients. This did not however 
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agree with the present study findings probably due to low numbers of participants who had the above 
characteristics. 
Some of the limitations of this study included the use of a single serological marker. Not all serological 
markers of HBV were used to for diagnosis of HBV therefore chances of leaving out possible occult cases positive 
for HBV DNA extraction. In the risk factors analysis, majority of participants who are at higher risk of HBV 
acquisition such as the known men who have sex with men and intravenous drug users could not participate in the 
study as they have their special clinics where they receive similar services as those offered in the comprehensive 
care centre where this study was done. Finally the current study was not able to analyse liver function enzymes 
(Aspartate transferase and Alanine transaminase) and viral load which would have shown relationship between 
HBV infection and clinical variables among those who are HIV-HBV co-infected. 
 
Conclusion 
The high HBV-HIV prevalence of 4.9 % among patients attending Malindi Sub-county hospital Comprehensive 
Care Centre is most likely driven by intravenous drug use and multiple sexual partners among the male gender. 
Genotype A was the most prevalent 9/10 (90%) while 1/10 (10%) belonged to genotype E an observation that 
relates well with the distribution of HBV genotypes among the Kenyan general population. There is therefore need 
to routinely diagnose HBV among new comprehensive care centres recruits to ensure proper therapeutic 
management using antiretroviral drugs. 
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